Gut Liver. 2023;17(1):108-118.

Potential of Gut Microbe-Derived Extracellular Vesicles to Differentiate Inflammatory Bowel Disease Patients from Healthy Controls.

, , , , , , ,

제1저자 허민, 박영수 · 교신저자 윤혁

PMID 36424722 PMC9840915 DOI 10.5009/gnl220081 IF 4.1 소화기내과

소속 (5)

Interdisciplinary Program of Bioinformatics, College of Natural Sciences, Seoul National University, Seoul, Korea.
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Department of Public Health Science, Graduate School of Public Health, Seoul, Korea.
Institute of Health and Environment, Seoul National University, Seoul, Korea.

Abstract

BACKGROUND/AIMS This study aimed to evaluate the potential of the stool microbiome and gut microbe-derived extracellular vesicles (EVs) to differentiate between patients with inflammatory bowel disease (IBD) and healthy controls, and to predict relapse in patients with IBD.

METHODS Metagenomic profiling of the microbiome and bacterial EVs in stool samples of controls (n=110) and patients with IBD (n=110) was performed using 16S rRNA sequencing and then compared. Patients with IBD were divided into two enterotypes based on their microbiome, and the cumulative risk of relapse was evaluated.

RESULTS There was a significant difference in the composition of the stool microbiome and gut microbe-derived EVs between patients with IBD and controls. The alpha diversity of the microbiome in patients with IBD was significantly lower than that in controls, while the beta diversity also differed significantly between the two groups. These findings were more prominent in gut microbe-derived EVs than in the stool microbiome. The survival curve tended to be different for enterotypes based on the gut microbe-derived EVs; however, this difference was not statistically significant (log-rank test, p=0.166). In the multivariable analysis, elevated fecal calprotectin (>250 mg/kg) was the only significant risk factor associated with relapse (adjusted hazard ratio, 3.147; 95% confidence interval, 1.545 to 6.408; p=0.002).

CONCLUSIONS Analysis of gut microbe-derived EVs is better at differentiating patients with IBD from healthy controls than stool microbiome analysis.

Keywords

Extracellular vesiclesInflammatory bowel diseasesMicrobiota

Figures

**Fig. 1** Taxonomic composition of the stool microbiome and gut microbe-derived extracellular vesicles (EVs) in patients with inflammatory bowel disease (IBD) and healthy controls. (A) Phylum level (stool microbiome); (B) phylum level (gut microbe-derived EVs); (C) genus level (stool microbiome); and (D) genus level (gut microbe-derived EVs).

**Fig. 2** Alpha diversity of the stool microbiome (A) and gut microbe-derived EVs (B) in patients with IBD and healthy controls. EV, extracellular vesicle; IBD, inflammatory bowel disease; OTUs, operational taxonomic units. *p<0.05, ^†p<0.01, ^‡p<0.001.

**Fig. 3** Principal coordinate analysis of the stool microbiome (A) and gut microbe-derived extracellular vesicles (B) in patients with inflammatory bowel disease (IBD) and healthy controls. PERMANOVA, permutational analysis of variance.

**Fig. 4** Cluster analysis based on the bacterial composition of the stools of patients with inflammatory bowel disease. (A) Enterotype based on the stool microbiome. (B) Enterotype based on gut microbe-derived extracellular vesicles.

**Fig. 5** Comparison of Kaplan-Meier survival curves according to enterotype. (A) Based on stool microbiome. (B) Based on gut microbe-derived extracellular vesicles.

그림 출처: PubMed Central 공개 논문 (PMC9840915)

Conflict of interest statement

CONFLICTS OF INTEREST . No potential conflict of interest relevant to this article was reported.

그 밖의 정보